News from the BioCity Campus

Study Health Market China: Drugs and Medical Biotechnology

China's healthcare market is one of the largest in the world. The market for pharmaceuticals and biopharmaceuticals is growing steadily due to the unrestrained demand for innovative drugs and diagnostics, but also for conventional drugs and generics.

German products are in demand in China, which opens up good business opportunities for local manufacturers. At the same time, the Chinese market is heavily regulated. Complex registration and approval procedures, strict regulations on pricing and sales make it difficult to get started. The study describes the most important aspects of market access for pharmaceuticals and biopharmaceuticals, introduces China's business culture, makes recommendations for successful market cultivation and provides information on key local partners.

The publication was created on behalf of the Health Economy Export Initiative and published by Germany Trade & Invest.

You can download the publication here

Source: Federal Ministry for Economic Affairs and Energy from September 10.09.2021th, XNUMX

previous news

iDiv: New building of the research center in Leipzig inaugurated

Michael Kretschmer, Bodo Ramelow and Dr. Reiner Haseloff and DFG Secretary General Heide Ahrens officially opened the new research building of the German Center for Integrative Biodiversity Research (iDiv) on Wednesday. Over 100 guests attended the event, which took place under strict hygiene protection measures. They learned what contribution iDiv is making and intends to make to solving the global biodiversity crises.


c-LEcta: Drug Master File for the use of the enzyme DENARASE® in the pharmaceutical industry accepted by the US FDA

c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, announces the submission of a master file for its best-selling product DENARASE®.